Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Viral Hepat
Hlavní autoři: Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379735/
https://ncbi.nlm.nih.gov/pubmed/30421537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13038
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky